Clear Search

Showing 8 results for “Gladman D”.

March 2024

TYK2: An emerging therapeutic target in rheumatic disease

Nat Rev Rheumatol 2024;20(4):232–40 DOI 10.1038/s41584-024-01093-w

TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases, including SLE, and could potentially have a safety profile that differs from other JAK inhibitors.

more…

December 2023
November 2023

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

Ann Rheum Dis 2023;83(1):15–29 DOI: 10.1136/ard-2023-224762

 The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

more…

May 2023
February 2023
September 2022
February 2022

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print

Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).

Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.

more…

Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print

Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.

more…